Advances in the Study of Metabolic Reprogramming in Gastric Cancer

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-05-14 DOI:10.1002/cam4.70948

Yu Rong, Yuanyin Teng, Xiaoying Zhou

{"title":"Advances in the Study of Metabolic Reprogramming in Gastric Cancer","authors":"Yu Rong, Yuanyin Teng, Xiaoying Zhou","doi":"10.1002/cam4.70948","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Gastric cancer is one of the most prevalent malignancies of the digestive system and is associated with a poor prognosis, particularly in advanced metastatic stages, where the 5-year survival rate is significantly low.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Recent research has demonstrated that metabolic reprogramming—including alterations in glucose, lipid, and amino-acid metabolism—plays a critical role in both the development and progression of this disease. To gain deeper insights into these metabolic shifts, scientists have increasingly employed metabolomics, a non-invasive technique that detects and quantifies small molecules within cancerous tissues, thereby enhancing prognostic assessments.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>Analyzing the metabolic profiles of gastric-cancer tissues can reveal significant changes in key metabolic pathways, which may open new avenues for targeted therapies and ultimately improve patient outcomes.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This article reviews recent advancements in the study of metabolic reprogramming in gastric cancer, aiming to identify potential therapeutic targets and offer new hope to patients.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 10","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70948","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70948","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Gastric cancer is one of the most prevalent malignancies of the digestive system and is associated with a poor prognosis, particularly in advanced metastatic stages, where the 5-year survival rate is significantly low.

Methods

Recent research has demonstrated that metabolic reprogramming—including alterations in glucose, lipid, and amino-acid metabolism—plays a critical role in both the development and progression of this disease. To gain deeper insights into these metabolic shifts, scientists have increasingly employed metabolomics, a non-invasive technique that detects and quantifies small molecules within cancerous tissues, thereby enhancing prognostic assessments.

Aim

Analyzing the metabolic profiles of gastric-cancer tissues can reveal significant changes in key metabolic pathways, which may open new avenues for targeted therapies and ultimately improve patient outcomes.

Conclusion

This article reviews recent advancements in the study of metabolic reprogramming in gastric cancer, aiming to identify potential therapeutic targets and offer new hope to patients.

Abstract Image

查看原文本刊更多论文

胃癌代谢重编程研究进展

胃癌是最常见的消化系统恶性肿瘤之一，预后较差，特别是在晚期转移期，其5年生存率明显较低。最近的研究表明，代谢重编程——包括葡萄糖、脂质和氨基酸代谢的改变——在该疾病的发生和进展中起着关键作用。为了更深入地了解这些代谢变化，科学家们越来越多地使用代谢组学，这是一种检测和量化癌组织内小分子的非侵入性技术，从而增强了预后评估。目的分析胃癌组织代谢谱，揭示关键代谢途径的显著变化，为靶向治疗开辟新途径，最终改善患者预后。结论本文综述了近年来胃癌代谢重编程的研究进展，旨在发现潜在的治疗靶点，为患者带来新的希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.